Enrolling and dosing is ongoing:
Phase 1 Clinical Trial of
LFD-200 in Rheumatoid Arthritis
By combining the precision of antibody-drug conjugates (ADCs) with the proven efficacy of glucocorticoids, we are unlocking a new class of therapies for autoimmune disorders
After a Phase 1a evaluation in healthy participants (Williams et al., EULAR Poster #1310, 2026), Lifordi is currently conducting a Phase 1b Multiple Ascending Dose (MAD) double-blind, randomized, placebo and active controlled study in patients with moderate-to-severe Rheumatoid Arthritis (RA). The aim of this Phase 1a/1b study is to assess the safety, efficacy, and biologic effects of LFD-200. In this 12-week study, patients with RA will be randomly assigned to receive oral prednisone, subcutaneous LFD-200, or a placebo.
Initial Phase 1a data in healthy participants showed LFD-200 was safe, well tolerated, demonstrated anti-inflammatory effects without affecting cortisol, and suggested potential for less frequent dosing.
The Phase 1a portion of this study is being conducted in Australia, and the Phase 1b portion in patients with RA is being conducted in Georgia, Moldova, Poland, and Ukraine.
For the Phase 1b portion of the trial, patients must have moderate-to-severe RA (DAS28-CRP score >3.2) while on a stable dose of methotrexate, be 18-75 years old, and have a BMI within 18-35 kg/m², among other criteria.
To learn more about this clinical trial, including additional key inclusion and exclusion criteria, please visit
clinicaltrials.gov or search NCT07207954.